A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder

@article{Thase2017AMO,
  title={A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder},
  author={Michael E. Thase and Yuko Asami and Dalia Ballas Wajsbrot and Kathleen M. Dorries and Matthieu Boucher and Elizabeth A Pappadopulos},
  journal={Current Medical Research and Opinion},
  year={2017},
  volume={33},
  pages={317 - 326}
}
Abstract Objective: To evaluate the short-term efficacy of venlafaxine extended release (ER) 75–225 mg/day compared with placebo for treating major depressive disorder (MDD) and to examine associations between baseline characteristics and efficacy outcomes in MDD patients treated with venlafaxine ER 75–225 mg/day. Research design and methods: This meta-analysis included published and unpublished short-term, double-blind, placebo-controlled, Wyeth/Pfizer sponsored studies of venlafaxine ER at… 
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
TLDR
The efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms is supported, and changes from baseline to final visit in Montgomery–Åsberg Depression Rating Scale total score and response and remission rates were analyzed.
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis
TLDR
Early improvement in symptom clusters significantly predicts symptomatic or functional remission at week 8 in patients with depression receiving desvenlafaxine or placebo, and patients without early improvement were less likely to remit.
Androgen deficit changes the response to antidepressant drugs in tail suspension test in mice
TLDR
It is suggested that not all antidepressant drugs are suitable for depression with androgen deficiency, as mice with low androgen were more prone to depression-like behaviors and the response to antidepressants changed under the condition of low androgens in mice.
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2
TLDR
The data support the notion that the antidepressant effect of venlafaxine involves a combination of serotonin transporter and norepinephrine transporter blockades.
Genotoxic and cytotoxic evaluation of venlafaxine in an acute and a subchronic assay in mouse
TLDR
Results suggest caution with venlafaxine and suggest a cytotoxic effect with the two high doses in the last two weeks was observed (a polychromatic erythrocyte mean decrease of 52% respect to the mean control value).
Genotoxic and cytotoxic evaluation of venlafaxine in an acute and a subchronic assay in mouse.
TLDR
Results suggest caution with venlafaxine and suggest a cytotoxic effect with the two high doses in the last two weeks was observed (a polychromatic erythrocyte mean decrease of 52% respect to the mean control value).

References

SHOWING 1-10 OF 53 REFERENCES
Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
  • M. Thase
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1997
TLDR
Venlafaxine XR was significantly more effective than placebo beginning at Week 2 on the CGI Severity scale, at Week 3 on the HAM-D depressed mood item, and at Week 4 on the MADRS; this superiority was maintained through Week 8.
The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
TLDR
It was demonstrated that 75 to 200 mg/day of venlafaxine twice daily produced a dose-related improvement in the primary efficacy parameters and in the onset of significant antidepressant effects, which was noted at weeks 1 to 2 with the highest dosage tested (200 mg/ day).
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study
TLDR
Venlafaxine ER effectively maintained response at doses ≤225 mg/day for up to 2.5 years in patients with recurrent MDD, consistent with those of the full data set.
Duloxetine and Venlafaxine-XR in the Treatment of Major Depressive Disorder: A Meta-Analysis of Randomized Clinical Trials
TLDR
Venlafaxine-XR tends to have a favorable trend in remission and response rates compared with duloxetine, however, dropout rates and adverse events did not differ and a direct comparison is warranted to confirm this tendency.
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
TLDR
Once-daily venlafaxine XR is effective and well tolerated for the treatment of major depression and concomitant anxiety and provides evidence for superiority over fluoxetine.
A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
TLDR
Venlafaxine, at dosages of 75-375 mg/day, is an effective and well-tolerated antidepressant, and with increasing dosage, greater efficacy and possibly more adverse effects will occur.
Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies
TLDR
This meta-analysis includes all published, randomized, double-blind, head-to-head trials, which compared venlafaxine and an SSRI in the treatment of MDD in adults, and shows that venl Lafaxine was superior to SSRIs in achieving remission and response.
Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity
TLDR
It is demonstrated that venlafaxine may be superior to SSRIs in achieving remission in both mild/moderate and severely depressed patients.
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
TLDR
The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients, and the results do not support previous findings that antidepressants show little benefit except for severe depression.
...
1
2
3
4
5
...